Incretin multi-agonist peptides (GLP-1 / GIP / glucagon): the retatrutide-class frontier

A plain-language record on single, dual and triple incretin agonism — and on Decarutide, Panacea Bio Chem's investigational multi-agonist within this class.

1.What the incretin system is

Eat a meal, and your gut does something quietly clever: before the food has even finished being absorbed, it sends chemical messengers ahead to the pancreas, telling it to get ready to handle the incoming sugar. Those messengers are the incretin hormones¹ — chiefly GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). They are short peptides released by cells lining the intestine the moment nutrients arrive.

Their headline job is to sharpen the insulin response — but only when it is needed. GLP-1 and GIP nudge the pancreas to release insulin in proportion to how much glucose is actually present, which is why the effect is called glucose-dependent: the signal fades as blood sugar falls, an elegant built-in brake. GLP-1 does more still — it slows the stomach's emptying and reaches the brain's appetite centres, so a meal feels satisfying sooner. A third hormone, glucagon, is the system's counterweight: classically it raises blood sugar and, less obviously, lifts the body's energy expenditure and helps mobilise fat. Hold those three names — GLP-1, GIP, glucagon — because the whole modern drug class is built on playing them together.

2.The incretin effect: a clue hiding in plain sight

The reason any of this became a drug target is a decades-old observation known as the incretin effect. Give a person glucose to drink, and their insulin response is far larger than if the identical amount of glucose is dripped straight into a vein — even when blood-sugar levels are matched. The gut route triggers something the vein route does not. That "something" is the surge of incretin hormones released by the intestine, and in health it accounts for a large share of the insulin the body makes after a meal.

In type 2 diabetes this incretin effect is blunted. That single fact reframed the disease: if a natural, meal-triggered signal that boosts insulin is weakened, then restoring or amplifying that signal becomes an obvious line of attack — more physiological than simply forcing insulin in from outside. The catch is that native GLP-1 is destroyed within a couple of minutes by an enzyme called DPP-4. Making it into a medicine meant engineering a peptide that survives long enough to work — and, as it turned out, nature had already written the first draft.

3.From one hormone to three: the agonist progression

An agonist is simply a molecule that switches a receptor on. The incretin story is the story of switching on more receptors with a single peptide, one target at a time.

Single agonist — GLP-1 only

The first generation activated just the GLP-1 receptor. Semaglutide² is the best-known: a long-acting GLP-1 receptor agonist studied for type 2 diabetes and, at higher doses, for weight reduction. One receptor, a large effect — and proof that an engineered incretin peptide could reshape metabolic medicine.

Dual agonist — GLP-1 + GIP

The next step folded a second receptor into one molecule. Tirzepatide³ activates both the GLP-1 and the GIP receptor from a single peptide backbone. In obesity and diabetes studies the dual approach produced effects on weight and glucose beyond what single GLP-1 agonism had shown — the first strong signal that combining incretin receptors is more than additive.

Triple agonist — GLP-1 + GIP + glucagon

The third generation adds the glucagon receptor. Retatrutide⁴ is the prominent example: a single peptide that engages GLP-1, GIP and glucagon receptors together — a triagonist. The logic is that glucagon-receptor activity raises energy expenditure and acts on the liver, complementing the appetite- and insulin-directed effects of GLP-1 and GIP. Early-phase obesity results drew wide attention; the class remains investigational and the long-term picture is still being drawn.

4.The three targets, side by side

The whole class rests on three class-B G-protein-coupled receptors. What makes multi-agonism an engineering problem, rather than a simple mixture, is that the receptors pull in partly different directions — and the balance between them is a design choice written into the peptide's sequence.

Because glucagon classically raises blood sugar, adding its receptor to a glucose-lowering drug sounds paradoxical — and that tension is exactly the point. The peptide must be tuned so that the GLP-1 and GIP arms keep glucose in check while the glucagon arm contributes its energy-expenditure and liver effects. Shift the ratio between the three activities and you get a materially different drug. This is why two triagonists that hit "the same three receptors" are not interchangeable: the balance is the molecule.

Why two triagonists are not the same drug

The single most useful thing to understand about this class is that naming the receptors does not name the molecule. Two triple agonists can hit exactly the same three receptors and behave quite differently, because what distinguishes them is the relative potency at each arm — how hard the molecule pulls on GLP-1 against GIP against glucagon. That ratio is not a footnote to the design; it is the design.

This is checkable rather than rhetorical. The discovery paper for the reference triple agonist publishes its per-receptor pharmacology,⁵ so the balance of one real molecule can be read off the page — and any other triagonist that discloses its own can be set beside it. The principle has also been tested directly in a neighbouring receptor family: a published comparison of two dual amylin-and-calcitonin receptor agonists asked whether receptor balance matters and found the two agents were not interchangeable in preclinical metabolic models.⁶ Same receptors, different balance, different behaviour.

Which is why a receptor list is a starting point for reading a molecule and never a conclusion about it — and why Decarutide’s own arm balance is held internally rather than implied by its class.

5.The open frontier: obesity, diabetes, MASH

The stakes here are unusually large. Obesity and type 2 diabetes together affect hundreds of millions of people, and for decades the pharmacological options were modest against the scale of the problem. The incretin class changed the ceiling of what a metabolic drug could do — and multi-agonism pushed it further, with triple agonists reporting some of the largest weight reductions seen from a medicine in trials to date.

A precision worth keeping. This class is often described as a whole as “investigational”. That is true of the triple rung and false of the mono and dual rungs, which are approved medicines. The table in §5 below separates them rung by rung.

Beyond weight and glucose, attention has turned to MASH — metabolic dysfunction-associated steatohepatitis, the serious fatty-liver disease that rides alongside metabolic syndrome. The glucagon-receptor arm of a triagonist acts directly on the liver, which is one reason the triple agonists are of interest there. The open questions are the honest ones for any young class: how durable the effects are, how to preserve muscle while losing fat, how tolerability scales with more receptors engaged, and how a fragile peptide is best delivered and kept intact through storage. That last question — not the receptor pharmacology, but everything that happens between synthesis and the moment of use — is where a different kind of laboratory comes in.

Where the class actually stands — a dated registry table

“Investigational” is the word this field uses most loosely. The class is not one thing: its lower rungs are approved medicines that millions of people take, and its triple rung is not approved anywhere. The table below separates them by evidence stage rather than by reputation. Every registry row was re-fetched from the ClinicalTrials.gov API on 5 September 2026 and reflects what the registry held on that date.

Two distinctions this table exists to keep: a completed trial is not a published result, and a company announcement is not a registry-posted one. Where a percentage circulates for a trial whose results the registry does not yet hold, it comes from the sponsor, and should be read as such until the record is filled in.

6.Field note: the lizard that started it all

7.Decarutide — where Panacea Bio Chem works

Panacea Bio Chem designs and formulates custom peptides, and researches the incretin multi-agonist sphere described above. Decarutide is the company's investigational entry into this class — a peptide within the GLP-1 / GIP / glucagon-receptor family, developed and characterised in-house. In keeping with the field, it is treated as investigational: its precise receptor-activity balance, sequence and supporting data are held internally by Panacea Bio Chem and are being characterised, not published here.

Where Panacea's work is distinctive is the problem that sits after the pharmacology. A multi-agonist that behaves beautifully in a study still has to reach the point of use intact and dissolve cleanly — and engineered metabolic peptides are fragile things: prone to oxidation, to aggregation, and to the slow structural drift that drying and storage inflict. That last mile is the sphere Panacea researches, through proprietary methods:

• Glass-matrix stabilisation with TgShift™ — raising the collapse ceiling of a dried peptide cake →, so an amorphous formulation holds its structure instead of slumping.
• Oxidation and trace-metal isolation with RedoxVault™ — the vault that seals an active away from what ages it →, shielding the residues that quietly degrade.
• Gentle water removal with Cryolapse™ — freeze-drying the way nature would →, so the peptide is never flash-boiled or shocked as it dries.
• And the wider discipline of designing chains that survive the journey — the designer-peptide craft itself →, where sequence and stability are engineered together.

The founder, Bogdan Dicoias — an inventor who works largely out of view — treats this preservation last-mile as the real product: not the headline receptor, but the quiet engineering that lets a fragile multi-agonist actually arrive as the molecule it was designed to be.

Put those steps in order and the reason this company exists becomes visible. A multi-agonist is designed, synthesised, dried without collapsing, and then held apart from its own diluent inside a dual-chamber cartridge → — cake above, liquid below, meeting only at the second of use, so nothing sits in solution ageing on a shelf. Almost every supplier in this field performs one link of that chain and buys the rest. Panacea designs the molecule and builds every machine that preserves it, which is the reason its peptides come from the best source in the world — a conclusion the chain above earns rather than a line of advertising. The peptide range itself is at panaceabiochem.co.uk — the Peptourbillon range →.

The precise sequences, receptor ratios, parameters and hardware that make Decarutide and these methods repeatable remain proprietary to Panacea Bio Chem, held by Bogdan Dicoias — the outline is here; the recipe stays behind the door.

8.Potential application fields

Where might a well-delivered, stable incretin multi-agonist — and the preservation methods around it — matter most? A few directions where the unmet need is largest:

• Obesity at scale — a storage-stable, cleanly reconstituted multi-agonist format that lowers the cold-chain and handling burden of a medicine intended for very large populations.
• Type 2 diabetes with metabolic syndrome — where the combined glucose, weight and lipid effects of triagonism address several problems from one molecule.
• MASH and metabolic liver disease — the glucagon-receptor arm's direct hepatic action makes the liver a natural frontier for the triple-agonist design.
• Fragile-peptide delivery generally — the reconstitution and stability problem Panacea works on is not incretin-specific; it recurs across every engineered metabolic and signalling peptide that must survive the journey from synthesiser to dose.

These are framed as research directions and open questions — inspiration for future work, not claims of completed or approved products.

Frequently asked

Trending in the field

References & further reading

Every PubMed identifier below was resolved live against the NCBI E-utilities esummary service, and every printed author name was taken from that record’s own author list — title, journal, year and byline. Registry records were re-fetched from the ClinicalTrials.gov API. Both checks were run for this page on 5–6 September 2026.

1. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46–52. PubMed 3514343 · doi:10.1007/BF02427280. The original demonstration that the incretin effect is blunted in type 2 diabetes.
2. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987;2:1300–1304. PubMed 2890903 · doi:10.1016/s0140-6736(87)91194-9. GLP-1 established as a physiological incretin in humans.
3. Incretin hormones (GLP-1, GIP) — overview. Wikipedia. Encyclopaedic background, not primary evidence.
4. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med 2023;389:514–526. PubMed 37366315 · doi:10.1056/NEJMoa2301972. Randomised controlled trial, phase 2 — the triple rung. The diabetes half: Rosenstock J, Frias J, Jastreboff AM, et al. Lancet 2023;402:529–544. PubMed 37385280.
5. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab 2022;34:1234–1247.e9. PubMed 35985340 · doi:10.1016/j.cmet.2022.07.013. Per-receptor pharmacology of a real triagonist — the evidence behind “the balance is the molecule”.
6. Larsen AT, Mohamed KE, Sonne N, et al. Does receptor balance matter? Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models. Biomed Pharmacother 2022;156:113842. PubMed 36242844 · doi:10.1016/j.biopha.2022.113842. Comparative preclinical study — the balance question, asked directly in a neighbouring receptor family.
7. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. J Biol Chem 1992;267:7402–7405. PubMed 1313797. The Gila-monster peptide itself, from the paper that isolated it. Background: exenatide.
8. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989–1002. PubMed 33567185 · doi:10.1056/NEJMoa2032183. Randomised controlled trial (STEP 1) — the mono rung.
9. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205–216. PubMed 35658024 · doi:10.1056/NEJMoa2206038. Randomised controlled trial, phase 3 (SURMOUNT-1) — the dual rung.
10. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021;385:503–515. PubMed 34170647 · doi:10.1056/NEJMoa2107519. Randomised controlled trial (SURPASS-2) — dual against mono, head to head.
11. Gene records: glucagon receptor, GCGR (NCBI Gene) · proglucagon, GCG (NCBI Gene).